Abstract:To the editor, Large variation in response to inhaled corticosteroids (ICS) has been reported in both asthma and chronic obstructive pulmonary disease (COPD), which may partly be explained by genetic factors. The transcriptome of the airways changes following ICS treatment,1 which may be directed by single nucleotide polymorphisms (SNPs), that affect deoxyribonucleic acid (DNA) methylation (methylation-Quantitative Trait Loci, meQTL). A strong and consistent response of the airways to ICS in both asthma and COPD patients1, 2 has been found, and severe childhood asthma has been associated with increased odds of COPD development in later life,3 showing that overlap between the diseases may exist. We hypothesised that preselection of steroid-inducible meQTL that affect DNA methylation upon ICS treatment may increase power to find SNPs that also clinically affect response to ICS and that these genetic variants might overlap between asthma and COPD. The aim of this study was to identify SNPs that affect change in DNA methylation in the airway wall upon ICS treatment, and to investigate whether these SNPs are associated with asthma exacerbations in children despite treatment with ICS. For the identification of meQTLs, we investigated 43 Dutch COPD patients from the Groningen and Leiden Universities study of Corticosteroids in Obstructive Lung Disease (GLUCOLD) study (Table S1).1 Longitudinal airway wall DNA methylation (EPIC 850 K array) and gene expression (ribonucleic acid-sequencing, RNA-seq) was collected from these patients pre- and post-6 months of fluticasone ± salmeterol (500/50 μg twice daily) treatment (Figure S1). We focused on methylation sites that previously were shown to be altered during ICS treatment (1049 CpG sites).4 This analysis identified 76 inducible meQTL caused by 71 independent SNPs with an false discovery rate (FDR) < 0.05 (Table S2). The most significant association was between cg13086983 and rs10917023, where the G allele (minor allele frequency: 7.7%) induced higher methylation (Beta: 0.849, p value: 4.21 × 10−06). Of these 76 CpG sites, 24 were associated with 24 gene transcripts (Table S3). The most significant association was found between the Cytosine-phosphate-Guanine (CpG) site cg08570199 and the CCDC80 gene (Beta coefficient: −1.249, p-value: 2.05 × 10−4; Figure 1A–D). The influence of genetics on the changes of methylation during corticosteroid treatment. (A) Inducible meQTL analysis of the change in cg08570199 methylation before and 6 months following ICS treatment in bronchial biopsies and the SNP rs9859566. (B) Change in CCDC80 gene expression before and 6 months following ICS treatment in bronchial biopsies separated by the genotype of rs9859566. (C) EQTM analysis of the change in cg08570199 methylation and CCDC80 gene expression following before and 6 months following ICS treatment in bronchial biopsies. (D) Diagram of the relative positions of rs9859566 and cg08570199 to the gene CCDC80 Subsequently, we investigated whether the identified meQTL were associated with asthma or COPD exacerbations despite ICS use in children with asthma and adult COPD patients, respectively. The asthma analysis was conducted performing a meta-analysis in eight cohort studies from the Pharmacogenomics in Childhood Asthma (PiCA) consortium5 stratified by European (n = 1515) or non-European descent (n = 1702) (see online supplementary Table and S4). Two outcomes were defined according to the American Thoracic Society/European Respiratory Society 2009 statement: (1) ‘any exacerbation’: hospitalisations, asthma-related emergency room visits, or oral corticosteroids (OCS) courses in the past 6–12 months and (2) OCS courses in the past 6–12 months. None of the identified meQTL were associated with the outcomes ‘any’ exacerbations and OCS courses in the past 6–12 months (Tables S5–S8). The COPD analysis was conducted in the Lung Health Study (LHS)-2, including 1116 COPD patients (ICS, n = 559 or placebo, n = 557) with lung function measurements over 3 years,6 where a previous pharmacogenomic analysis focusing on genotype-by-ICS treatment effect on 3 years of FEV1 changes (estimated as slope) was investigated for the 71 SNPs None of the identified meQTL SNPs were associated with FEV1 decline after multiple testing correction (Table S9). In conclusion, corticosteroid inducible meQTL analysis enabled us to identify a set of functional SNPs that may be useful for future (functional) studies. Although our results indicate that overlap in genetic response to steroids may exist, comparing the epigenetic responses in adult COPD patients to clinical effects in children with asthma, we do acknowledge that additional, disease and age-specific effects may be present. However, these SNPs were not significantly associated with exacerbations and OCS courses in children nor with the slope of FEV1 in adults with COPD. Elise M. A. Slob contributed to the statistical analysis and interpretation of the data, design of tables and figures, writing of the original draft and review and editing. Alen Faiz contributed to the conception and design, statistical analysis and interpretation of data, design of tables and figures, writing of the original draft and review and editing. Jos van Nijnatten contributed to the statistical analysis and design of the tables and figures and review and editing. Susanne J. H. Vijverberg contributed to the subject recruitment, data collection and review and editing. Maria Pino-Yanes contributed to the subject recruitment, data collection and review and editing. Esteban G. Burchard contributed to the subject recruitment, data collection and review and editing. Uroš Potočnik contributed to the subject recruitment, data collection and review and editing. Colin Palmer contributed to the subject recruitment, data collection and review and editing. Steve Turner contributed to the subject recruitment, data collection and review and editing. Katia Verhamme contributed to the subject recruitment, data collection and review and editing. Somnath Mukhopadhyay contributed to the subject recruitment, data collection and review and editing. Leila Karimi contributed to the subject recruitment, statistical analysis and interpretation of the data, data collection and review and editing. Fook Tim Chew contributed to the subject recruitment, data collection and review and editing. Wim Timens contributed to the subject recruitment, data collection and review and editing. PH contributed to the subject recruitment, data collection and review and editing. Mariëlle W. Pijnenburg contributed to the interpretation of the data and review and editing. Maarten van den Berge contributed to the subject recruitment, conception and design, data collection and review and editing. Hananeh Aliee contributed to the subject recruitment, data collection and review and editing. Vojko Berce contributed to the subject recruitment, data collection and review and editing. Corry A. Brandsma contributed to the subject recruitment, data collection and review and editing. Margaret Neighbors contributed to the subject recruitment, data collection and review and editing. Michele A. Grimbaldeston contributed to the subject recruitment, statistical analysis and data interpretation, data collection and review and editing. Gaik W. Tew contributed to the subject recruitment, data collection and review and editing. Antonio Espuela-Ortiz contributed to the statistical analysis and interpretation of the data and review and editing. Yang Yie Sio contributed to the statistical analysis and interpretation of the data and review and editing. Javier Perez-Garcia contributed to the statistical analysis and interpretation of the data and review and editing. Merve Kutlu contributed to the statistical analysis and interpretation of the data and review and editing. Don D. Sin contributed to the subject recruitment, data collection and review and editing. Xuan Li contributed to the subject recruitment, data collection and review and editing. Anke H. Maitland contributed to the subject recruitment, data collection and review and editing. Cyrielle Maroteau contributed to the statistical analysis and interpretation of the data and review and editing. Gerard H. Koppelman contributed to the conception and design, statistical analysis and interpretation of data, writing of the original draft, review and editing and is the principle investigator. All authors approved the final version of the manuscript. The GLUCOLD study (for which these are secondary analyses) was supported by the Netherlands Organisation for Scientific Research (NWO), the Dutch Asthma Foundation, GlaxoSmithKline, the University Medical Center Groningen, and Leiden University Medical Center. Genentech Inc. funded the GLUCOLD bronchial biopsy RNA sequencing project. E.M.A. Slob, S.J.H. Vijverberg, A.H. Maitland-van der Zee, G.H. Koppelman and M.W. Pijnenburg are conducting the PUFFIN trial that is supported by the Lung Foundation Netherlands, grant number 5.1.16.094. The PACMAN cohort study was funded by a strategic alliance between GlaxoSmithKline and Utrecht Institute for Pharmaceutical Sciences. The SLOVENIA study was financially supported by the Slovenian Research Agency (research core funding No. P3-0067) and from the SysPharmPedia grant, co-financed by the Ministry of Education, Science and Sport Slovenia (MIZS) (contract number C3330-16-500106). The Genes-environments and Admixture in Latino Americans (GALA II) Study and the Study of African Americans, Asthma, Genes and Environments (SAGE) were supported in part by the Sandler Family Foundation, the American Asthma Foundation, the RWJF Amos Medical Faculty Development Program, Harry Wm. and Diana V. Hind Distinguished Professor in Pharmaceutical Sciences II, the National Heart, Lung, and Blood Institute of the National Institutes of Health R01HL117004, R01HL128439, R01HL135156, X01HL134589, R01HL141992, R01HL141845, National Institute of Health and Environmental Health Sciences R01ES015794, R21ES24844, the National Institute on Minority Health and Health Disparities P60MD006902, RL5GM118984, R01MD010443, and R56MD013312, the Tobacco-Related Disease Research Program under Award Number 24RT-0025, 27IR-0030 and the National Human Genome Research Institute U01HG009080. The genotyping service of PAGES was carried out at CEGEN-PRB3-ISCIII, supported by grant PT17/0019 of the PE I+D+i 2013–2016, funded by ISCIII and ERDF. Maria Pino-Yanes was funded by the Ramón y Cajal Program by the Spanish Ministry of Science, Innovation, and Universities (MICIU) (RYC-2015-17205) and by a grant by MICIU, the State Research Agency, and the European Regional Development Fund from the European Union (MICIU/AEI/FEDER, UE, SAF2017-83417R). Esther Herera-Luis was supported by a MICIU fellowship (PRE2018-083837). Javier Perez-Garcia was also supported by a Ph.D. fellowship (FPU19/02175) granted by MICIU. Antonio Espuela-Ortiz was supported by a fellowship granted by MICIU/ULL (M-ULL). The SLOVENIA study was financially supported by the Slovenian Research Agency (research core funding No. P3-0067) and from the SysPharmPedia grant, co-financed by the Ministry of Education, Science and Sport Slovenia (MIZS) (contract number C3330-16-500106). F.J. Theis reports receiving consulting fees from Roche Diagnostics GmbH and Cellarity Inc., and ownership interest in Cellarity, Inc. and Dermagnostix. E.M.A. Slob, A. Faiz, S.J.H. Vijverberg, H. Aliee, J. van Nijnatten, P. Hiemstra, C. Maroteau, C. Palmer, M. Kutlu, S. Turner, S. Mukhopadhyay, M. Gorenjak, C.A. Brandsma, L. Karimi, Y.Y. Sio, C. Longo and M.W. Pijnenburg have nothing to disclose. F.T. Chew reports grants from Singapore Ministry of Education Academic Research Fund, Singapore Immunology Network, National Medical Research Council (NMRC) (Singapore), Biomedical Research Council (BMRC) (Singapore), and the Agency for Science Technology and Research (A*STAR) (Singapore), during the conduct of the study; and consulting fees from Sime Darby Technology Centre; First Resources Ltd; Genting Plantation, and Olam International, outside the submitted work. M. Pino-Yanes reports grants from the Spanish Ministry of Science, Innovation, and Universities, the State Research Agency, and the European Regional Development Fund from the European Union (MICIU/AEI/FEDER, UE). E. Herrera-Luis and J. Perez-Garcia report a fellowships from MICIU. A. Espuela-Ortiz declares a fellowship granted by MICIU/ULL. E.G. Burchard reports grants from the National Institutes of Health, the Tobacco-Related Disease Research Program, the Sandler Family Foundation, the American Asthma Foundation, the Amos Medical Faculty Development Program from the Robert Wood Johnson Foundation, and from the Harry Wm. and Diana V. Hind Distinguished Professorship in Pharmaceutical Sciences II. W. Timens reports fees to the UMCG from Roche Diagnostics/Ventana, personal fees from Merck Sharp Dohme, Bristol-Myers-Squibb and AbbVie, outside the submitted work. G.H. Koppelman reports grants from Lung Foundation of the Netherlands, UBBO EMMIUS Foundation, TETRI Foundation, TEVA the Netherlands, Vertex, GSK, European Union (H2020 Prominent Grant), outside the submitted work; and he has acted on advisory board meetings of GSK and Pure IMS, outside the submitted work. A.H. Maitland-van der Zee has received research grants outside the submitted work from GSK, Boehringer Íngelheim and Vertex, she is the PI of a P4O2 (Precision Medicine for more Oxygen) public private partnership sponsored by Health Holland involving many private partners that contribute in cash and/or in kind (Boehringer Ingelheim, Breathomix, Fluidda, Ortec Logiqcare, Philips, Quantib-U, Smartfish, SODAQ, Thirona, TopMD and Novartis), and she has served in advisory boards for AstraZeneca, GSK and Boehringer Ingelheim with money paid to her institution. Dr. van den Berge reports grants to University from GlaxoSmithKline, Novartis, Genentech, outside the submitted work. Dr. Potočnik reports grants from Slovenian Research Agency, grants from Ministry of Education, Science and Sport Slovenia (MIZS), during the conduct of the study. M. Grimbaldeston, G.W. Tew and M. Neighbors are employees of Genentech Inc., a Member of the Roche Group. K. Verhamme works for a research department which receives/received unconditional research grants from Yamanouchi, Pfizer-Boehringer Ingelheim, Novartis, GSK, Chieisi, Amgen, UCB, none of which are related to the content of this work. F.J. Theis acknowledges support by the BMBF (grant #L031L0214A, grant# 01IS18036B and grant# 01IS18053A) and by the Helmholtz Association's Initiative and Networking Fund through Helmholtz AI [grant number: ZT-I-PF-5-01] and sparse2big [grant number ZT-I-007]. V. Berce reports grants from Slovenian Research Agency, grants from Ministry of Education, Science and Sport Slovenia (MIZS), during the conduct of the study. The Netherlands Organisation for Scientific Research; the Dutch Asthma Foundation; GlaxoSmithKline, the University Medical Center Groningen; Leiden University Medical Center. Genentech Inc.; Lung Foundation Netherlands, Grant/Award Number: number 5.1.16.094; GlaxoSmithKline and Utrecht Institute for Pharmaceutical Sciences; Slovenian Research Agency, Grant/Award Number: P3-0067; SysPharmPedia grant; the Ministry of Education, Science and Sport Slovenia (MIZS), Grant/Award Number: C3330-16-500106; Sandler Family Foundation; The American Asthma Foundation, the RWJF Amos Medical Faculty Development Program; The National Heart, Lung, and Blood Institute of the National Institutes of Health, Grant/Award Number: R01HL117004, R01HL128439, R01HL135156, X01HL134589, R01HL141992, R01HL141845; National Institute of Health and Environmental Health Sciences, Grant/Award Number: R01ES015794, R21ES24844; The National Institute on Minority Health and Health Disparities, Grant/Award Number: P60MD006902, RL5GM118984, R01MD010443, and R56MD013312; the Tobacco-Related Disease Research Program, Grant/Award Number: 24RT-0025, 27IR-0030; National Human Genome Research Institute, Grant/Award Number: U01HG009080; ISCIII and ERDF; Ramón y Cajal Program by the Spanish Ministry of Science, Innovation, and Universities, Grant/Award Number: RYC-2015-17205; MICIU, FPU19/02175; The State Research Agency; The European Union, Grant/Award Number: MICIU/AEI/FEDER, UE, SAF2017-83417R; MICIU fellowship, Grant/Award Number: PRE2018-083837; MICIU/ULL (M-ULL); Slovenian Research Agency, Grant/Award Number: P3-0067; SysPharmPedia, The Ministry of Education, Science and Sport Slovenia, Award Number: C3330-16-500106; Roche Diagnostics GmbH and Cellarity Inc. Research data are not shared. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Abstract:Lung function impairment underlies chronic obstructive pulmonary disease (COPD) and predicts mortality. In the largest multi-ancestry GWAS meta-analysis of lung function to date, comprising 580,869 participants, 1020 independent association signals identified 559 genes supported by ≥2 criteria from a systematic variant-to-gene mapping framework. These genes were enriched in 29 pathways. Individual variants showed heterogeneity across ancestries, age and smoking groups, and collectively as a genetic risk score (GRS) showed strong association with COPD across ancestry groups. We undertook phenome-wide association studies (PheWAS) for selected associated variants, and trait and pathway-specific GRS to infer possible consequences of intervening in pathways underlying lung function. We highlight new putative causal variants, genes, proteins and pathways, including those targeted by existing drugs. These findings bring us closer to understanding the mechanisms underlying lung function and COPD, and should inform functional genomics experiments and potentially future COPD therapies. ### Competing Interest Statement M. D. Tobin and L. V. Wain receive funding from GSK for collaborative research projects outside of the submitted work. I. P. Hall has funded research collaborations with GSK, Boehringer Ingelheim and Orion. M. H. Cho has received grant funding from GSK and Bayer, and speaking or consulting fees from AstraZeneca, Illumina, and Genentech. I. Sayers has funded research collaborations with GSK, Boehringer Ingelheim and Orion outside of the submitted work. ### Funding Statement A. Guyatt: Wellcome Trust Institutional Strategic Support Fund (204801/Z/16/Z), BHF Accelerator Award (AA/18/3/34220). C. John: Medical Research Council Clinical Research Training Fellowship (MR/P00167X/1). A. T. Williams: BBSRC CASE studentship with GSK. L. V. Wain: GSK/British Lung Foundation Chair in Respiratory Research. M. D. Tobin: Wellcome Trust Investigator Award (WT202849/Z/16/Z). M.D. Tobin and L. V. Wain: MRC (MR/N011317/1). M.D. Tobin and I. P. Hall hold NIHR Senior Investigator Awards. I. Sayers: MRC (G1000861) A. Morris: Wellcome Trust (WT098017 & WT064890) The research was supported by BREATHE - The Health Data Research Hub for Respiratory Health (MC\_PC\_19004). The research was partially supported by the NIHR Leicester Biomedical Research Centre and the NIHR Nottingham Biomedical Research Centre; views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The funders had no role in the design of the Mendelian randomization analyses. This research was funded in whole, or in part, by the Wellcome Trust. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. Cohort and study-group specific funding: ALHS: The Agricultural Lung Health Study (ALHS) was supported by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences (Z01-ES102385, Z01-ES049030, Z01-ES043012, and for ABW, contract no. HHSN273201600003I) and the National Cancer Institute (Z01-CP010119). ALHS also supported in part by American Recovery and Reinvestment Act (ARRA) funds through NIEHS contract number N01-ES-55546. National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS), Intramural Research Program. Contract number HHSN273201600003I (funding to Annah B. Wyss). ALHS thank the numerous study staff at Social & Scientific Systems, Inc. who played a role in the data collection, and acknowledge Dr. Nathan Gaddis, RTI, International for assitance performing gentoype QC and HRC imputation for ALHS. B58C: Acknowledge use of phenotype and genotype data from the British 1958 Birth Cohort DNA collection, funded by the Medical Research Council grant G0000934 and the Wellcome Trust grant 068545/Z/02. Genotyping for the B58C-WTCCC subset was funded by the Wellcome Trust grant 076113/B/04/Z. The B58C-T1DGC genotyping utilized resources provided by the Type 1 Diabetes Genetics Consortium, a collaborative clinical study sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Allergy and Infectious Diseases (NIAID), National Human Genome Research Institute (NHGRI), National Institute of Child Health and Human Development (NICHD), and Juvenile Diabetes Research Foundation International (JDRF) and supported by U01 DK062418. B58C-T1DGC GWAS data were deposited by the Diabetes and Inflammation Laboratory, Cambridge Institute for Medical Research (CIMR), University of Cambridge, which is funded by Juvenile Diabetes Research Foundation International, the Wellcome Trust and the National Institute for Health and Care Research Cambridge Biomedical Research Centre; the CIMR is in receipt of a Wellcome Trust Strategic Award (079895). The B58C-GABRIEL genotyping was supported by a contract from the European Commission Framework Programme 6 (018996) and grants from the French Ministry of Research. BHS: National Health and Medical Research Council (NHMRC), Ideas Grant 2003629 (funding to Benjamin H. Mullin). Department of Health Western Australia, Merit Award 1186046 (funding to Benjamin H. Mullin). The Busselton Health Study is supported by the Government of Western Australia (Office of Science and Department of Health), the City of Busselton and private donations to the Busselton Population Medical Research Institute. Generous support for the 1994/5 follow-up study was also received from Healthway, Western Australia, and support from The Great Wine Estates of the Margaret River region of Western Australia. We also thank the WA Country Health Service and acknowledges the numerous Busselton community volunteers who assisted with data collection and the study participants from the Shire of Busselton. COPDGene and ECLIPSE (COPD case-control studies): received support from the NIH, grant numbers: R01HL149861 (funding to Cho), R01HL135142 (funding to Cho, Hobbs), R01HL137927 (funding to Cho, Silverman), R01HL089856 (funding to Cho, Silverman), R01HL147148 (funding to Cho, Silverman), K08HL136928 (funding to Hobbs), P01HL114501 (funding to Silverman) and P01HL132825 (funding to Silverman, Cho). The COPDGene project ([NCT00608764][1]) was supported by Award Number U01 HL089897 and Award Number U01 HL089856 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health. The COPDGene project is also supported by the COPD Foundation through contributions made to an Industry Advisory Board that has included AstraZeneca, Bayer Pharmaceuticals, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer, and Sunovion. The ECLIPSE study ([NCT00292552][2]; GSK code SCO104960) was funded by GlaxoSmithKline. The COPDGene, ECLIPSE, GenKOLS, and NETT/NAS studies would like to acknowledge Pooja Srinivasa and Chandan Pavuluri for their programming support. CHS: This CHS research was supported by NHLBI contracts HHSN268201200036C, HHSN268200800007C, HHSN268201800001C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, 75N92021D00006; and NHLBI grants U01HL080295, R01HL085251, R01HL087652, R01HL105756, R01HL103612, R01HL120393, and U01HL130114 with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided through R01AG023629 from the National Institute on Aging (NIA). A full list of principal CHS investigators and institutions can be found at CHS-NHLBI.org. The provision of genotyping data was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. CROATIA-Korcula/Split/Vis: MRC Human Genetics Unit core funding, the Ministry of Science, Education and Sport in the Republic of Croatia (216-1080315-0302) and the Croatian Science Foundation (grant 8875) (funding to I. Rudan, C. Hayward, S.M. Kerr, O. Polasek, V. Vitart, and J. Marten). CKB: The CKB baseline survey and the first re-survey were supported by the Kadoorie Charitable Foundation in Hong Kong. Long-term follow-up was supported by the Wellcome Trust (212946/Z/18/Z, 202922/Z/16/Z, 104085/Z/14/Z, 088158/Z/09/Z), the National Key Research and Development Program of China (2016YFC0900500, 2016YFC0900501, 2016YFC0900504, 2016YFC1303904), and the National Natural Science Foundation of China (91843302). DNA extraction and genotyping was funded by GlaxoSmithKline and the UK Medical Research Council (MC-PC-13049, MC-PC-14135). The project is supported by core funding from the UK Medical Research Council (MC\_UU\_00017/1,MC\_UU\_12026/2, MC\_U137686851), Cancer Research UK (C16077/A29186; C500/A16896), and the British Heart Foundation (CH/1996001/9454) to the Clinical Trial Service Unit and Epidemiological Studies Unit and to the MRC Population Health Research Unit at Oxford University. CKB gratefully acknowledges the participants in the study, the members of the survey teams in each of the 10 regional centres, and the project development and management teams based at Beijing, Oxford and the 10 regional centres. EPIC-Norfolk: received support from the MRC, grant numbers: MR/N003284/1, MC-UU\_12015/1, MC\_UU\_00006/1, MC\_PC\_13048 and C864/A14136, and the Cancer Research UK, grant number C864/A14136. EPIC acknowledge all study participants that have been part of the project. EXCEED: Recruitment was supported by the EXtended Cohort for E-health, Environment and DNA (EXCEED) study. EXCEED is supported by the University of Leicester, the National Institute for Health and Care Research Leicester Respiratory Biomedical Research Centre, the Wellcome Trust (WT 202849), and Cohort Access fees from studies funded by the Medical Research Council (MRC), Biotechnology and Biological Sciences Research Council, National Institute for Health and Care Research, the UK Space Agency, and GlaxoSmithKline. It was previously supported by Medical Research Council grant G0902313. EXCEED is supported by BREATHE - The Health Data Research Hub for Respiratory Health (UKRI\_PC\_19004) in partnership with SAIL Databank. BREATHE is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. FHS: The Framingham Heart Study is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with Boston University (Contract No. N01-HC-25195, HHSN268201500001I and 75N92019D00031). Generation Scotland: Received support from Chief Scientist Office of the Scottish Government Health Directorate (grant: CZD/16/6), the Scottish Funding Council (grant: HR03006), the Medical Research Council UK, and the Wellcome Trust Strategic Award STratifying Resilience and Depression Longitudinally (STRADL) (grant: 104036/Z/14/Z). Genotyping of the GS:SFHS samples was carried out by the Edinburgh Clinical Research Facility, University of Edinburgh. Acknowledge all the families who took part in the Generation Scotland: Scottish Family Health Study, the general practitioners and Scottish School of Primary Care for their help in recruiting them, and the whole Generation Scotland team, which includes academic researchers, IT staff, laboratory technicians, statisticians and research managers. H2000: Finnish Foundation for Cardiovascular Research (funding to Veikko Salomaa). HCHS/SOL: The Hispanic Community Health Study/Study of Latinos is a collaborative study supported by contracts from the National Heart, Lung, and Blood Institute (NHLBI) to the University of North Carolina (HHSN268201300001I / N01-HC-65233), University of Miami (HHSN268201300004I / N01-HC-65234), Albert Einstein College of Medicine (HHSN268201300002I / N01-HC-65235), University of Illinois at Chicago (HHSN268201300003I / N01- HC-65236 Northwestern Univ), and San Diego State University (HHSN268201300005I / N01-HC-65237). The following Institutes/Centers/Offices have contributed to the HCHS/SOL through a transfer of funds to the NHLBI: National Institute on Minority Health and Health Disparities, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, NIH Institution-Office of Dietary Supplements. The Genetic Analysis Center at the University of Washington was supported by NHLBI and NIDCR contracts (HHSN268201300005C AM03 and MOD03). HUNT: The genotyping in HUNT was financed by the National Institutes of Health and Care Research; University of Michigan; the Research Council of Norway; the Liaison Committee for Education, Research and Innovation in Central Norway; and the Joint Research Committee between St Olavs hospital and the Faculty of Medicine and Health Sciences, NTNU. The genetic investigations of the HUNT Study is a collaboration between researchers from the K.G. Jebsen Center for Genetic Epidemiology, NTNU and the University of Michigan Medical School and the University of Michigan School of Public Health. The K.G. Jebsen Center for Genetic Epidemiology is financed by Stiftelsen Kristian Gerhard Jebsen; Faculty of Medicine and Health Sciences, NTNU, Norway. KORA F4 and KORA S3: The KORA study was initiated and financed by the Helmholtz Zentrum Munchen - German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria. Furthermore, KORA research was supported within the Munich Center of Health Sciences (MC-Health), Ludwig-Maximilians-Universitat, as part of LMUinnovativ and by the Competence Network Asthma and COPD (ASCONET), network COSYCONET (subproject 2, BMBF FKZ 01GI0882) funded by the German Federal Ministry of Education and Research (BMBF). LBC1936: Phenotype collection in the Lothian Birth Cohort 1936 was supported by Age UK (The Disconnected Mind project) and the University of Edinburgh. Genotyping was funded by the Biotechnology and Biological Sciences Research Council (BBSRC -BB/F019394/1). MESA: MESA and the MESA SHARe project are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. The MESA Lung Study is supported by R01-HL077612 and R01-HL093081. Support for MESA is provided by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159, 75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161, 75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163, 75N92020D00004, N01-HC-95164, 75N92020D00007, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079, UL1-TR-001420, UL1-TR-001881, and DK063491. Funding for SHARe genotyping was provided by NHLBI Contract N02-HL-64278. MESA Family is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support is provided by grants and contracts R01HL071051, R01HL071205, R01HL071250, R01HL071251, R01HL071258, R01HL071259, by the National Center for Research Resources, Grant UL1RR033176, and the National Center for Advancing Translational Sciences, Grant UL1TR001881. This publication was developed under Science to Achieve Results (STAR) research assistance agreements, No. RD831697 (MESA Air), and RD-83830001 (MESA Air Next Stage), awarded by the U.S Environmental protection Agency. It has not been formally reviewed by the EPA. The views expressed in this document are solely those of the authors and the EPA does not endorse any products or commercial services mentioned in this publication. Genotyping was performed at Affymetrix (Santa Clara, California, USA) and the Broad Institute of Harvard and MIT (Boston, Massachusetts, USA) using the Affymetrix Genome-Wide Human SNP Array 6.0. MESA is also supported by the NHLBI, grant: R01-HL-131565 (funding to Ani Manichaikul). NEO: : Received support from the Netherlands Cardiovascular Research Initiative, grant number: CVON2014-02 ENERGISE (funding to Dennis Mook-Kanamori),VELUX Stiftung \[grant number 1156\] (funding to Dennis Mook-Kanamori), and the Dutch Science Organization, grant number: ZonMW-VENI grant 916.14.023 (funding to Dennis Mook-Kanamori). The authors of the NEO study thank all individuals who participated in the Netherlands Epidemiology in Obesity study, all participating general practitioners for inviting eligible participants and all research nurses for collection of the data. We thank the NEO study group, Pat van Beelen, Petra Noordijk and Ingeborg de Jonge for the coordination, lab and data management of the NEO study. The genotyping in the NEO study was supported by the Centre National de Genotypage (Paris, France), headed by Jean-Francois Deleuze. The NEO study is supported by the participating Departments, the Division and the Board of Directors of the Leiden University Medical Center, and by the Leiden University, Research Profile Area Vascular and Regenerative Medicine. Tariq Faquih was supported by the King Abdullah Scholarship Program and King Faisal Specialist Hospital & Research Centre (No. 1012879283). NFBC1966 and NFBC1986: NFBC1966 and 1986 have received financial support from the Academy of Finland (project grants 104781, 120315, 129269, 1114194, 24300796, Center of Excellence in Complex Disease Genetics and SALVE), University Hospital Oulu, Biocenter, University of Oulu, Finland (75617), NIHM (MH063706, Smalley and Jarvelin), Juselius Foundation, NHLBI grant 5R01HL087679-02 through the STAMPEED program (1RL1MH083268-01), NIH/NIMH (5R01MH63706:02), the European Commission (EURO-BLCS, Framework 5 award QLG1-CT-2000-01643), ENGAGE project and grant agreement HEALTH-F4-2007-201413, EU FP7 EurHEALTHAgeing -277849, the Medical Research Council, UK (G0500539, G0600705, G1002319, PrevMetSyn/SALVE) and the MRC, Centenary Early Career Award. The program is currently being funded by the H2020 DynaHEALTH action (grant agreement 633595), EU H2020-HCO-2004 iHEALTH Action (grant agreement 643774), EU H2020-PHC-2014 ALEC Action (grant agreement No. 633212), EU H2020-SC1-2016-2017 LifeCycle Action (grant agreement No 733206), EU H2020-MSCA-ITN-2016 CAPICE Action (grant agreement 721567), Academy of Finland EGEA-project (285547) and MRC Grant nro MR/M013138/1. ORCADES: Supported by the Chief Scientist Office of the Scottish Government (CZB/4/276, CZB/4/710), the Royal Society, the MRC Human Genetics Unit, Arthritis Research UK and the European Union framework program 6 EUROSPAN project (contract no. LSHG-CT-2006-018947) (funding to James F. Wilson). ORCADES DNA extractions were performed at the Wellcome Trust Clinical Research Facility in Edinburgh. ORCADES acknowledge the people of Orkney for sharing their data and samples. PIVUS: Received support from Versus Arthritis, grant number: 21754 (funding to Andrew Morris), the Wellcome Trust under awards WT098017, WT064890, WT090532, Uppsala University and Uppsala University Hospital, the Swedish Research Council and the Swedish Heart-Lung Foundation. The PIVUS investigators express their deepest gratitude to the study participants. QBB: Received funding from Qatar Foundation (QF) by the Biomedical Research Program at Weill Cornell Medicine in Qatar, grant: NPRP11C-0115-180010 (funding to Karsten Suhre and Omar Albagha) Qatar biobank and Qatar Genome Program are both Research, Development & Innovation entities within Qatar Foundation for Education, Science and Community Development. Raine: Funded by National Health and Medical Research Council (NHMRC) of Australia, grants: 572613, 403981 and 1059711. The authors gratefully acknowledge the NH&MRC for their long term funding to the study over the last 30 years and also the following institutes for providing funding for Core Management of the Raine Study: The University of Western Australia (UWA), Curtin University, the Raine Medical Research Foundation, the UWA Faculty of Medicine, Dentistry and Health Sciences, the Telethon Kids Institute, the Womens and Infants Research Foundation (King Edward Memorial Hospital), Murdoch University, The University of Notre Dame (Australia), and Edith Cowan University. The authors gratefully acknowledge the assistance of the Western Australian DNA Bank (National Health and Medical Reserach Council of Australia National Enabling Facility). This work was supported by resources provided by the Pawsey Supercomputing Centre with funding from the Australian Government and Government of Western Australia. Rotterdam: Funded by FWO, grant: 3G037618 (funding to Sara Wijnant). SAPALDIA: Swiss National Science Foundation (33CS30-148470/1&2, 33CSCO-134276/1, SPIROMICS 33CSCO-108796, 324730\_135673, 3247BO-104283, 3247BO-104288, 3247BO-104284, 3247-065896, 3100-059302, 3200-052720, 3200-042532, 4026-028099, PMPDP3\_129021/1, PMPDP3_141671/1), the Federal Office for the Environment, the Federal Office of Public Health, the Federal Office of Roads and Transport, the cantons government of Aargau, Basel-Stadt, Basel-Land, Geneva, Luzern, Ticino, Valais, and Zurich, the Swiss Lung League, the cantons Lung League of Basel Stadt/ Basel Landschaft, Geneva, Ticino, Valais, Graubunden and Zurich, Stiftung ehemals Bundner Heilstatten, SUVA, Freiwillige Akademische Gesellschaft, UBS Wealth Foundation, Talecris Biotherapeutics GmbH, Abbott Diagnostics, European Commission 018996 (GABRIEL) and the Wellcome Trust (WT 084703MA). The SAPALDIA study could not have been done without the help of the study participants, technical and administrative support and the medical teams and field workers at the local study sites. Local fieldworkers : Aarau: S Brun, G Giger, M Sperisen, M Stahel, Basel: C Burli, C Dahler, N Oertli, I Harreh, F Karrer, G Novicic, N Wyttenbacher, Davos: A Saner, P Senn, R Winzeler, Geneva: F Bonfils, B Blicharz, C Landolt, J Rochat, Lugano: S Boccia, E Gehrig, MT Mandia, G Solari, B Viscardi, Montana: AP Bieri, C Darioly, M Maire, Payerne: F Ding, P Danieli A Vonnez, Wald: D Bodmer, E Hochstrasser, R Kunz, C Meier, J Rakic, U Schafroth, A Walder. SHIP: Received support from the Federal Ministry of Education and Research, grants: 01ZZ9603, 01ZZ0103, 01ZZ0403 and 03ZIK012, and the German Research Foundation, grant: GR 1912/5-1. SPIROMICS: Supported by contracts from the NIH/NHLBI (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN268200900019C, HHSN268200900020C), grants from the NIH/NHLBI (U01 HL137880 and U24 HL141762), and supplemented by contributions made through the Foundation for the NIH and the COPD Foundation from AstraZeneca/MedImmune; Bayer; Bellerophon Therapeutics; Boehringer-Ingelheim Pharmaceuticals, Inc.; Chiesi Farmaceutici S.p.A.; Forest Research Institute, Inc.; GlaxoSmithKline; Grifols Therapeutics, Inc.; Ikaria, Inc.; Novartis Pharmaceuticals Corporation; Nycomed GmbH; ProterixBio; Regeneron Pharmaceuticals, Inc.; Sanofi; Sunovion; Takeda Pharmaceutical Company; and Theravance Biopharma and Mylan. The NHLBI also supported SPIROMICS, grants: R01-HL-131565 (funding to Xiaowei Hu and Ani Manichaikul) and R01-HL-153248 (funding to Ani Manichaikul). The authors thank the SPIROMICS participants and participating physicians, investigators and staff for making this research possible. More information about the study and how to access SPIROMICS data is available at [www.spiromics.org][3]. The authors would like to acknowledge the University of North Carolina at Chapel Hill BioSpecimen Processing Facility for sample processing, storage, and sample disbursements (<http://bsp.web.unc.edu/>). We would like to acknowledge the following current and former investigators of the SPIROMICS sites and reading centers: Neil E Alexis, MD; Wayne H Anderson, PhD; Mehrdad Arjomandi, MD; Igor Barjaktarevic, MD, PhD; R Graham Barr, MD, DrPH; Patricia Basta, PhD; Lori A Bateman, MSc; Surya P Bhatt, MD; Eugene R Bleecker, MD; Richard C Boucher, MD; Russell P Bowler, MD, PhD; Stephanie A Christenson, MD; Alejandro P Comellas, MD; Christopher B Cooper, MD, PhD; David J Couper, PhD; Gerard J Criner, MD; Ronald G Crystal, MD; Jeffrey L Curtis, MD; Claire M Doerschuk, MD; Mark T Dransfield, MD; Brad Drummond, MD; Christine M Freeman, PhD; Craig Galban, PhD; MeiLan K Han, MD, MS; Nadia N Hansel, MD, MPH; Annette T Hastie, PhD; Eric A Hoffman, PhD; Yvonne Huang, MD; Robert J Kaner, MD; Richard E Kanner, MD; Eric C Kleerup, MD; Jerry A Krishnan, MD, PhD; Lisa M LaVange, PhD; Stephen C Lazarus, MD; Fernando J Martinez, MD, MS; Deborah A Meyers, PhD; Wendy C Moore, MD; John D Newell Jr, MD; Robert Paine, III, MD; Laura Paulin, MD, MHS; Stephen P Peters, MD, PhD; Cheryl Pirozzi, MD; Nirupama Putcha, MD, MHS; Elizabeth C Oelsner, MD, MPH; Wanda K O Neal, PhD; Victor E Ortega, MD, PhD; Sanjeev Raman, MBBS, MD; Stephen I. Rennard, MD; Donald P Tashkin, MD; J Michael Wells, MD; Robert A Wise, MD; and Prescott G Woodruff, MD, MPH. The project officers from the Lung Division of the National Heart, Lung, and Blood Institute were Lisa Postow, PhD, and Lisa Viviano, BSN. YFS: The Young Finns Study has been financially supported by the Academy of Finland: grants 286284, 134309 (Eye), 126925, 121584, 124282, 129378 (Salve), 117787 (Gendi), and 41071 (Skidi); the Social Insurance Institution of Finland; Competitive State Research Financing of the Expert Responsibility area of Kuopio, Tampere and Turku University Hospitals (grant X51001); Juho Vainio Foundation; Paavo Nurmi Foundation; Finnish Foundation for Cardiovascular Research; Finnish Cultural Foundation; Tampere Tuberculosis Foundation; Emil Aaltonen Foundation; Yrjo Jahnsson Foundation; Signe and Ane Gyllenberg Foundation; Diabetes Research Foundation of Finnish Diabetes Association; and EU Horizon 2020 (grant 755320 for TAXINOMISIS). TwinsUK: Received support from Fight for Sight, grant: Ref 5037/5038 (funding to Karina Patasova). UKHLS: The UK Household Longitudinal Study was funded by grants from the Economic and Social Research Council (ES/H029745/1) and the Wellcome Trust (WT098051). These data are from Understanding Society: The UK Household Longitudinal Study, which is led by the Institute for Social and Economic Research at the University of Essex and funded by the Economic and Social Research Council. The data were collected by NatCen and the genome wide scan data were analysed by the Wellcome Trust Sanger Institute. The Understanding Society DAC have an application system for genetics data and all use of the data should be approved by them. The application form is at: <https://www.understandingsociety.ac.uk/about/health/data>. Full list of authors: Michaela Benzeval(1), Jonathan Burton(1), Nicholas Buck(1), Annette Jackle(1), Meena Kumari(1), Heather Laurie(1), Peter Lynn(1), Stephen Pudney(1), Birgitta Rabe(1), Dieter Wolke(2): 1) Institute for Social and Economic Research; 2) University of Warwick. VIKING: Supported by a MRC Human Genetics Unit quinquennial programme grant QTL in Health and Disease. VIKING DNA extractions and genotyping were performed at the Edinburgh Clinical Research Facility, University of Edinburgh. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: All participants provided written informed consent and studies were approved by local Research Ethics Committees and/or Institutional Review boards. ALHS: Informed consent was obtained from all participants and the study was approved by the IRB at National Institute of Environmental Health Sciences (NIEHS). ALSPAC: Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. Informed consent for the use of data collected via questionnaires and clinics was obtained from participants following the recommendations of the ALSPAC Ethics and Law Committee at the time. ARIC: The ARIC study has been approved by Institutional Review Boards (IRB) at all participating institutions: University of North Carolina at Chapel Hill IRB, Johns Hopkins University IRB, University of Minnesota IRB, and University of Mississippi Medical Center IRB. Study participants provided written informed consent at all study visits. B58C: The South East Research Ethics Committee of the (UK) National Health Service gave ethical approval for the British 1958 birth cohort (B58C) component of this study (REC references 01/1/044 and 06/MRE01/28). BHS: Human Ethics committee of The University of Western Australia gave ethical approval for this work Boston: The Mass General Brigham Institutional Review Board gave ethical approval for this work. CHS: Ethics committees/IRBs of Wake Forest University; University of California, Davis; Johns Hopkins University; University of Pittsburgh; University of Vermont; and University of Washington gave ethical approval for this work. CKB: All participants provided written informed consent at each survey visit, allowing access to their medical records and long-term storage of biosamples for future unspecified medical research purposes, without any feedback of results to the individuals concerned. Ethical approval was obtained from the Oxford Tropical Research Ethics Committee, the Ethical Review Committees of the Chinese Centre for Disease Control and Prevention, Chinese Academy of Medical Sciences, and the Institutional Review Board (IRB) at Peking University. The Chinese Ministry of Health approved the study at the start in 2004 (including export of plasma samples to Oxford), and also approved electronic linkage to health insurance records in 2011. Raw genotyping data were exported from China to the Oxford CKB International Coordinating Centre under Data Export Approvals 2014-13 and 2015-39 from the Office of Chinese Human Genetic Resource Administration. Croatia: The Ethical board of the University of Split, School of Medicine, Croatia gave ethical approval for this work. EPIC: The Norfolk (UK) Research Ethics Committee gave ethical approval for this work. EXCEED: The original EXCEED study was approved by the Leicester Central Research Ethics Committee (Ref: 13/EM/0226). Substantial amendments have been approved by the same Research Ethics Committee for the collection of new data relating to the COVID-19 pandemic, including the COVID-19 questionnaires and antibody testing. FHS: All participants provided written informed consent and this study was approved by the Institutional Review Board of the Boston University Medical Campus. FinnTwin: The study was approved by the local ethics committees (University Hospitals of Helsinki, Turku, Tampere, Kuopio and Oulu) and was conducted following the guidelines of the Declaration of Helsinki. All participants gave their written informed consent. GS: Ethical approval for the GS:SFHS study was received from the Tayside Committee on Medical Research Ethics (on behalf of the National Health Service), ref 05/S1401/89. Generation Scotland obtained Research Tissue Bank approval from the East of Scotland Research Ethics Service (on behalf of NHS Scotland), ref 20/ES/0021. H2000: The Ethics Committee of the National Public Health Institute gave ethical approval for the Health 2000 project in Sept. 29, 1999. A later amendment has been approved by the Ethics Committee of the Hospital District of Helsinki and Uusimaa at the National Public Health Institute in May 31, 2000. HCHS: This study was approved by the institutional review boards (IRBs) at each field center, where all participants gave written informed consent, and by the Non-Biomedical IRB at the University of North Carolina at Chapel Hill, to the HCHS/SOL Data Coordinating Center. All IRBs approving the study are: Non-Biomedical IRB at the University of North Carolina at Chapel Hill. Chapel Hill, NC; Einstein IRB at the Albert Einstein College of Medicine of Yeshiva University. Bronx, NY; IRB at Office for the Protection of Research Subjects (OPRS), University of Illinois at Chicago. Chicago, IL; Human Subject Research Office, University of Miami. Miami, FL; Institutional Review Board of San Diego State University. San Diego, CA. HUNT: Regional Committees for Medical and Health Research Ethics (REK 2015/616) gave ethical approval for this work. KORA: The ethics committee of the Bavarian Chamber of Physicians (Munich, Germany) gave ethical approval for this work. LBC1936: Ethics permission for the Lothian Birth Cohort 1936 (LBC1936) was obtained from the Multi-Centre Research Ethics Committee for Scotland (MREC/01/0/56) and the Lothian Research Ethics Committee (LREC/2003/2/29). MESA: All participants provided informed consent and the protocols of MESA were approved by the IRBs of collaborating institutions and the National Heart, Lung and Blood Institute. NEO: The Medical Ethics committee of the Leiden University Medical Centre approved The Netherlands Epidemiology of Obesity (NEO) study under protocol P08.109. The NEO study is also registered at [clinicaltrials.gov][4] under number NL21981.058.08 / P08.109. All participants gave written informed consent. ORCADES: All ORCADES participants gave written informed consent and the study was approved by Research Ethics Committees in Orkney, Aberdeen (North of Scotland REC), and South East Scotland REC, NHS Lothian (reference: 12/SS/0151). PIVUS: The Ethics Committee of the University of Uppsala approved the study, and the participants gave their informed consent. QBB: All participants gave informed consent. Institutional Review Board approval was obtained from the Hamad Medical Corporation Ethics Committee. Raine: Ethics approval for the original pregnancy cohort and subsequent follow-ups were granted by the Human Research Ethics Committee of King Edward Memorial Hospital, Princess Margaret Hospital, the University of Western Australia, and the Health Department of Western Australia. Parents, guardians and young adult participants provided written informed consent either before enrolment or at data collection at each follow-up. Rotterdam: The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare and Sport (Population Screening Act WBO, license number 1071272-159521-PG). All participants provided written informed consent to participate in the study and to have their information obtained from treating physicians. SAPALDIA: All procedures in this cohort study were conducted in accordance with the World Medical Associations Declaration of Helsinki and Declaration of Taipei. Written informed consent was obtained from the study participants prior to health examination and blood sample collection. The study protocols of this multi-centric long-term study with baseline and follow-up assessments were approved by Swiss national overarching ethics committees and by regional cantonal ethics committees for each time point of data collection. The SAPALDIA cohort study was approved by the ethics committee of the medical faculty of the University of Lausanne, Switzerland, for the baseline examination (SAPALDIA1) in 1989; and by the Supra-regional Ethics Committee for Clinical Research (UREK approval No 123/00) of the Swiss Academy of Medical Sciences for the second examination (SAPALDIA2) in September 2001; and given the multi-centric design of the long-term cohort, by multiple cantonal ethics committees for the third examination (SAPALDIA3) in 2009 (ethics committee of the Department of Health and Social Affairs of Aargau, approval No 2009/056, ethics committee of both Basel, approval No 219/09, cantonal ethics committee of Zurich, approval No 52/09, departmental ethics committee for Internal Medicine and Community Medicine of Geneva, approval No 09-174, cantonal commission for Medical Ethics of Valais, approval No033/09, cantonal Commission for Ethics in Human Research of Vaud, approval No 200/09, cantonal Ethics Committee of Ticino, approval No CE2276). SHIP: The proposed clinical study (study title: Full-body MRI SHIP-2/SHIP-Trend interim report and project extension) was reviewed on April 28, 2009 by the Ethics Committee of the Faculty of Medicine at the Ernst-Moritz-Arndt-University of Greifswald. A trial plan adapted to the results of this consultation was received by the office of the Ethics Committee on 02nd of September 2009. The majority of the Ethics Committee found that there were no ethical or legal concerns about continuing the project as described or about including project extension. Therefore, the Ethics Committee grants approval for the proposed study. Reference number: BB 39/08a. SPIROMICS: The SPIROMICS study was approved by the Institutional Review Boards at each of the cooperating institutions: Columbia University IRB 2 (AAAE9315), University of Iowa IRB-01 (201308719), Johns Hopkins IRB-5 (NA_00035701), UCLA Medical IRB 1 (MIRB1) (10001740/18-000403), University of Michigan IRBMED B1 Board (HUM00036346/ HUM00141222), National Jewish Health IRB (HS2678), UCSF IRB Parnassus Panel (10-03169), Temple University IRB A2 (21416), U of Alabama at Birmingham IRB #2 (120906004), University of Illinois IRB #3 (2013-0939), University of Utah IRB Panel Review Board 5 (00027298/ 00108836), Wake Forest University IRB #5 (00012805/00048727), UNC Non-Biomedical IRB (10-0048), UCLA Medical IRB 1 (MIRB1) (18-000458), and University of Iowa IRB-01 (201003733). All participants provided written informed consent. The research conformed to the principles of the Helsinki Declaration. TwinsUK: Twins provided informed written consent and the study was approved by St. Thomas Hospital Research Ethics Committee (REC Ref: EC04/015). UKHLS: The United Kingdom Household Longitudinal Study has been approved by the University of Essex Ethics Committee and informed consent was obtained from every participant. VIKING: All participants gave informed consent and the study was approved by the South East Scotland Research Ethics Committee. YFS: The Ethics Committee, Hospital District of Southwest Finland gave favourable ethical opinion of the protocol. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00608764&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F18%2F2022.05.11.22274314.atom [2]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT00292552&atom=%2Fmedrxiv%2Fearly%2F2022%2F05%2F18%2F2022.05.11.22274314.atom [3]: https://www.spiromics.org [4]: http://clinicaltrials.gov

A genome-wide analysis of the response to inhaled β2-agonists in chronic obstructive pulmonary disease

Prevalence of abnormal spirometry in individuals with a smoking history and no known obstructive lung disease

Integration of Genomic and Genetic Approaches Implicates IREB2 As a COPD Susceptibility Gene.

Association of Bronchial Steroid Inducible Methylation Quantitative Trait Loci with Asthma and Chronic Obstructive Pulmonary Disease Treatment Response

A Genome-Wide Association Study of Bronchodilator Response in Asthmatics

Genome-Wide Association Analysis of Blood Biomarkers in Chronic Obstructive Pulmonary Disease

Genome-wide Association Analysis in Asthma Subjects Identifies SPATS2L As a Novel Bronchodilator Response Gene.

Pharmacodynamic genome-wide association study identifies new responsive loci for glucocorticoid intervention in asthma

Emphysema Progression and Lung Function Decline Among Angiotensin Converting Enzyme Inhibitors and Angiotensin-Receptor Blockade Users in the COPDGene Cohort

A Genome-Wide Association Study in Chronic Obstructive Pulmonary Disease (COPD): Identification of Two Major Susceptibility Loci

Multi-ancestry Genome-Wide Association Analyses Improve Resolution of Genes and Pathways Influencing Lung Function and Chronic Obstructive Pulmonary Disease Risk

A Genome-Wide Association Study of Chronic Obstructive Pulmonary Disease in Hispanics

Childhood pneumonia increases risk for chronic obstructive pulmonary disease: the COPDGene study

Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials

Association of corticotropin-releasing hormone receptor-2 genetic variants with acute bronchodilator response in asthma

A Large-Scale Multi-ancestry Genome-wide Study Accounting for Smoking Behavior Identifies Multiple Significant Loci for Blood Pressure

Multi-ancestry genome-wide association study reveals novel genetic signals for lung function decline

Genome-wide association analyses for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets

The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update

Assessing the contribution of rare genetic variants to phenotypes of chronic obstructive pulmonary disease using whole-genome sequence data

Multi-ancestry genome-wide association study improves resolution of genes, pathways and pleiotropy for lung function and chronic obstructive pulmonary disease